SAN DIEGO, May 31, 2017 /PRNewswire/ -- Viking Therapeutics,
Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical
company focused on the development of novel therapies for metabolic
and endocrine disorders, today announced that its chief executive
officer, Brian Lian, Ph.D., will
deliver corporate presentations at two upcoming investor
conferences. Dr. Lian will present at the 7th
Annual LD Micro Invitational, being held June 6-7, 2017 in Los
Angeles and the 2017 Marcum Microcap Conference, being held
June 15-16, 2017 in New York
City.
Details of these presentations are as follows:
- 7th Annual LD Micro
Invitational
Time/Date: 8:30
a.m. PT on Tuesday, June 6,
2017
Location: Luxe Sunset Boulevard Hotel, Los Angeles
Room: Track 1
- 2017 Marcum Microcap Conference
Time/Date: 3:00
p.m. ET on Thursday, June 15,
2017
Location: Grand Hyatt Hotel, New
York
Room: Broadway – Conference Level
To access live webcasts of Viking's presentations, when
available, please visit "Webcasts & Presentations" within the
News & Events section of Viking's Investors page at
www.vikingtherapeutics.com. Additionally, replays of webcasts will
be available on the Viking website.
About Viking Therapeutics, Inc.
Viking Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development of novel, first-in-class or best-in-class therapies for
metabolic and endocrine disorders. The company's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. Viking has exclusive worldwide rights to a portfolio
of five therapeutic programs in clinical trials or preclinical
studies, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated. The company's clinical programs
include VK5211, an orally available, non-steroidal selective
androgen receptor modulator, or SARM, in Phase 2 development for
the treatment and prevention of lean body mass loss in patients who
have undergone hip fracture surgery, VK2809, a small molecule
thyroid beta agonist in Phase 2 development for
hypercholesterolemia and fatty liver disease, and VK0612, a
first-in-class, orally available drug candidate in Phase 2
development for type 2 diabetes. Viking is also developing
novel and selective agonists of the thyroid beta receptor for GSD
Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage
programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-upcoming-investor-conferences-300465597.html
SOURCE Viking Therapeutics, Inc.